IDEXX Laboratories (NASDAQ:IDXX) announced on Wednesday, April 1, 2026, the official launch of the IDEXX Cancer Dx™ Panel in the United Kingdom.
This expansion marks a significant milestone in the company’s global pet healthcare strategy, initially focusing on the early detection of lymphoma—one of the most prevalent and aggressive cancers in dogs.
The IDEXX Cancer Dx™ Panel is a specialized blood test designed to be seamlessly integrated into both diagnostic panels for symptomatic pets and routine wellness screenings for healthy, at-risk dogs.
A key clinical advantage of the test is its ability to identify a lymphoma signal up to eight months before physical clinical signs become apparent, providing veterinarians with a critical window for intervention and treatment planning.
The UK launch follows a highly successful introduction in North America in 2025, where nearly 6,000 veterinary practices across the United States and Canada have already adopted the test.
Consumer demand in the UK appears equally robust; recent research indicates that 71% of British pet owners are interested in proactive cancer screening for their animals.
With 1 in 4 dogs expected to face a cancer diagnosis in their lifetime, lymphoma accounts for nearly 25% of those cases.
To encourage widespread adoption among UK practices, IDEXX has set veterinarian pricing starting at £22.50.
The company’s established laboratory infrastructure will support a rapid turnaround time, with results typically available to clinics within 3 to 5 business days.
Management emphasized that the IDEXX Cancer Dx™ Panel is more than just a diagnostic tool; it is a fundamental shift toward "proactive wellness care" that prioritizes quality of life and longevity.